Trial Profile
Clinical Controlled Trial on Extinction of Opioidergic Binge Eating Disorder (BED) With Intranasal Naloxone Administration
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2017
Price :
$35
*
At a glance
- Drugs Naloxone (Primary)
- Indications Binge-eating disorder
- Focus Therapeutic Use
- 15 Jun 2017 According to an Opiant Pharmaceuticals media release, the study results are expected to be independently published in a scientific journal.
- 27 Mar 2013 Results will be presented at the 166th Annual Meeting of the American Psychiatric Association.
- 03 May 2012 Primary endpoint 'Binge-frequency' has been met.